How to develop treatments for biologically heterogeneous "diseases".
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22679178.
- Also identified by DOI 10.1158/1078-0432.CCR-12-1586 and PMC identifier 4135717.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The standard paradigm for the design of phase III clinical trials is not suitable for evaluation of molecularly targeted treatments in biologically heterogeneous groups of patients. Here, we comment on alternative clinical trial designs and propose a prospective discovery/evaluation framework for using tumor genomics in the design of phase III trials.
Medical subject headings
- Antibodies, Monoclonal
- Carcinoma, Non-Small-Cell Lung
- Clinical Trials, Phase III as Topic
- Lung Neoplasms
- Research Design